AN2 Therapeutics Inc [ANTX] stock is trading at $1.08, up 2.86%. An important factor to consider is whether the stock is rising or falling in short-term value. The ANTX shares have gain 4.85% over the last week, with a monthly amount glided 2.86%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
AN2 Therapeutics Inc [NASDAQ: ANTX] stock has seen the most recent analyst activity on August 09, 2024, when Leerink Partners downgraded its rating to a Market Perform and also revised its price target to $1 from $5. Previously, Evercore ISI downgraded its rating to Underperform on August 09, 2024. On July 03, 2024, upgrade upgraded it’s rating to Outperform but maintained its price target of $5 on the stock. JMP Securities upgraded its rating to a Mkt Outperform but stick to its price target of $6 on April 02, 2024. Leerink Partners downgraded its rating to a Market Perform and reduced its price target to $7 on February 13, 2024. Oppenheimer downgraded its rating to Perform for this stock on February 12, 2024. In a note dated February 12, 2024, JMP Securities downgraded an Mkt Perform rating on this stock.
AN2 Therapeutics Inc [ANTX] stock has fluctuated between $0.87 and $22.22 over the past year. Currently, Wall Street analysts expect the stock to reach $8.75 within the next 12 months. AN2 Therapeutics Inc [NASDAQ: ANTX] shares were valued at $1.08 at the most recent close of the market. An investor can expect a potential return of 710.19% based on the average ANTX price forecast.
Analyzing the ANTX fundamentals
Gross Profit Margin for this corporation currently stands at 0.5% with Operating Profit Margin at -889.64%, Pretax Profit Margin comes in at -808.21%, and Net Profit Margin reading is -808.21%. To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is -0.55 and Total Capital is -0.72.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.0533 points at the first support level, and at 1.0267 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1133, and for the 2nd resistance point, it is at 1.1467.
Ratios To Look Out For
For context, AN2 Therapeutics Inc’s Current Ratio is 10.61. On the other hand, the Quick Ratio is 10.61, and the Cash Ratio is 2.64.
Transactions by insiders
Recent insider trading involved RA Capital Healthcare Fund LP, Affiliate, that happened on Aug 15 ’24 when 1.7 million shares were purchased. Affiliate, RA Capital Nexus Fund II, L.P. completed a deal on Aug 15 ’24 to buy 0.3 million shares. Meanwhile, 10% Owner Leonard Braden Michael bought 1.5 million shares on Aug 14 ’24.
